

Index

A

ABVD chemotherapy, 201–205, 210, 211, 225
Activation-induced cytosine deaminase, 93
Adolescent and young adult Hodgkin lymphoma (AYAHL), 159, 160, 162, 165–168, 171, 173, 181, 185
Adverse effects (AE), 207–209, 226
Allogeneic stem cell transplantation (allo-SCT), 209, 224
Anaplastic large cell lymphoma (ALCL), 20, 142, 144–147
Anthracyclines, 4, 211
Antibody drug conjugates (ADC), 222, 225
Antigen presentation, 70
Antitumor immune responses, 78
Appendectomy, 168
Array CGH, 119
Ataxia-telangiectasia mutated gene (ATM), 176
Autoimmune lymphoproliferative syndrome (ALPS), 95
Autologous stem cell transplantation (ASCT), 206–209, 211, 222, 223
Avelumab, 227

B

B-cell non-Hodgkin lymphoma (B-NHL), 128, 130, 135–139
B-cell receptor (BCR), 38, 42, 43, 92, 97–99, 130
B cells, 48
 asymptomatic infection of, 92
 GC B cells, 37, 38, 41–43
 in vitro studies, 42
 lymphomas, 129

 normal, 37, 40, 47
 post-GC B cells, 37
Bendamustine, 207, 211, 225, 227
Bleomycin, 200, 211, 225
Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP), 201, 206
BLIMP1 α , 99
BLIMP1 β , 99
Brentuximab vedotin (BV), 206, 209, 210
 ASCT, bridge to, 223–225
 CD30, 222
 first-in-man phase I trial, 222
 relapsed/refractory HL post-ASCT, 222
BZLF1, 99, 101

C

cAMP response element-binding protein-binding protein (CREBBP), 77
Cardiovascular toxicity, 8
Castleman disease (CD), 23, 25
 CD30, 68, 73, 74
 CD40, 92, 97
 CD58, 77
 CD70, 72, 74
 CD137, 72
Cell-free DNA, 39
Chemokines, 66, 199
Chromosomal translocations, 43, 45
Classic Reed-Sternberg cells
 immunophenotype, 16, 18
 and inflammatory cells, 22

- Classical Hodgkin lymphoma (CHL), 15, 61, 91, 128, 158, 221
- ALCL, 144
 - CD4⁺ T cells and macrophages, 129
 - in composite lymphomas, 134
 - EBV role in (*see* Epstein-Barr virus (EBV))
 - EBV-positive, 17
 - genetic lesions, 45
 - JAK/STAT signaling in, 47
 - LDHL, 25–26
 - LRHL, 23–24
 - MCHL, 19–23
 - MCL, 136
 - NHL, 130
 - NSHL, 19–20
 - PMBL, 141
 - subtypes, 16
- Class II transactivator (CIITA), 77, 143
- Clinical features, Hodgkin lymphoma
- clinical history, 2–3
 - elderly patients, 6
 - evaluation and recommended testing, 3–4
 - immunocompromised patients, 6
 - patient follow-up and survivorship, 7–8
 - patterns of disease progression, 2
 - pregnancy, 6
 - prognostic factors, 4–5
 - symptoms, 1–2
- Combined modality therapy (CMT), 201–203, 212
- Composite lymphomas
- cellular origin of, 134
 - clonal relationship of, 129–134
 - definition, 128
 - diagnosis of, 129
 - genetic lesions, 136
- Computerized tomography (CT), 1, 3, 7, 211
- Connective tissue growth factor (CTGF), 64
- Constitutional symptoms, 2, 6
- Cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin (COPP-EBV-CAD), 205
- Cyclosporin A, 91
- Cysteinyl-leukotriene (CysLT) type 1 receptor, 69–70
- Cytarabine, 207
- Cytokines, 17, 39, 45–47, 62, 64–69
- Cytotoxic T cells (CTLs), 61, 65, 70, 72–74, 77, 78
- D**
- Dacarbazine, 211
- Dexa-BEAM, 207
- Dexamethasone, high-dose cytarabine, and cisplatin (DHAP), 206
- Diffuse large B-cell lymphoma (DLBCL), 95, 112, 128, 135, 137, 139
- Discoidin domain receptor 1 (DDR1), 102
- DNA methyltransferases, 97
- Doxorubicin, 200, 211
- E**
- EBNA1. *See* Epstein-Barr virus nuclear antigen-1 (EBNA1)
- EBV. *See* Epstein-Barr virus (EBV)
- Entinostat, 226
- Eosinophils, 61, 64, 68, 69, 72
- Eotaxin, 99
- Epidemiology, Hodgkin lymphoma, 159–163, 181–184
- adult lifestyle, 168
 - age-specific incidence rates, 159–162
 - body size and reproductive factors, 165–166
 - childhood infections, 167
 - clustering, 169–170
 - comorbid conditions, 171–173
 - EBV, 163–165
 - familial risk, 173–175
 - family structure, 166–167
 - family studies, 175–177
 - genetic risk factors, 175
 - heritability, 184
 - HLA type, 177–183
 - occupation and environment, 170–171
 - socioeconomic status, 165
 - tonsillectomy and appendectomy, 167–168
- Epstein-Barr virus (EBV), 17, 139, 163, 165
- B cells, asymptomatic infection of, 92, 93
 - CHL, 17
 - classical Hodgkin lymphoma
 - detection of EBV, 93–94
 - EBNA1, 96
 - epidemiology, 94–95
 - LMPI, 97
 - LMP2, 98
 - lytic cycle, 98–99
 - microenvironment, 98–102
 - pathogenesis, 42–43

MCHL, 22
 NSHL, 19
 origin of, 96
 Epstein-Barr virus nuclear antigen-1
 (EBNA1), 17, 92, 94, 96
 Etoposide, 200, 207, 211
 Etoposide, vinblastine, adriamycin (EVA), 213
 Everolimus, 226, 227
 Extranodal presentations, 2

F

Fertility preservation, 4
 FFTF. *See* Freedom from treatment failure
 (FFTF)
 Fibrosis, 64
 Formalin-fixed paraffin-embedded tumor
 (FFPET) tissue, 199
 Freedom from first progression
 (FFFP), 205
 Freedom from treatment failure (FFTF),
 200–202, 204

G

Galectin-9, 72
 Gemcitabine, 207
 Gene expression profiling (GEP), 199
 Gene mutations, 76
 Genetic lesions, NLPHL, 118, 119
 Genome-wide association studies (GWAS),
 75, 178, 180–184
 Genomic aberrations, 76
 Genomic instability, 43
 Germinal centre (GC), 37, 92, 96, 97, 135
 Germinal centre (GC) B cells, 37, 38, 41–43,
 48, 135, 140
 Germline mutations/polymorphisms, 46
 Graft-versus-host disease (GVHD), 224

H

Hallmark cells, 20
 Hallmark chromosomal translocations, 130, 136
 Hepatocyte growth factor (HGF), 69
 Heritability, 184–185
 Herpesvirus, 91
 Highly active antiretroviral therapy
 (HAART), 95
 Histone deacetylases (HDAC) inhibitors, 65,
 66, 73, 225, 226

Hodgkin and Reed/Sternberg (HRS) cells,
 36–39, 61, 66, 128, 129, 136, 139,
 144, 199
 API transcription factors, 48
 BATF3, 48
 CCL5, 68
 CD40, 73
 CD70, 72
 CD80 and CD86, 72
 CD137, 72
 cellular origin of
 B cell, 37
 GC B cells, 37
 Ig and TCR gene, 37
 IgV genes, 37
 molecular studies, 36
 T cell/cytotoxic markers, 37
 chromosomal translocations, 43
 cytokine receptors on, 47
 DNA/RNA, peripheral blood, 39–40
 features of, 36
 galectin-9, 72
 genomic instability, 43
 IL-6, 66
 IL-7, 67
 IL-9, 67
 IL-13, 67
 IL-15, 68
 IL-21, 68
 immune escape mechanism for, 70
 JAK/STAT pathway, 45, 47
 karyotype, 43
 lost B cell phenotype, 40–42
 MAP kinase signaling, 48
 MET, 48
 MHC, loss of, 45
 and microenvironment (*see* Microenvironment)
 NF- κ B activity, 44, 47
 OX40L, 72
 PD-L1, 65, 72
 PI3K/AKT pathway, 48
 and receptor tyrosine kinases, 47
 STAT activation in, 47
 survival factors, 68
TNFAIP3 mutations, 45
 Hodgkin lymphoma (HL), 4, 5, 7, 8, 15, 61,
 141–147
 advanced-stage, 204–206
 antitumor immune responses, 78
 ASCT, 207
 cell lines, 36, 38, 39

- Hodgkin lymphoma (HL) (*cont.*)
 characteristics for, 5
 cHL, 128, 221
 ALCL, 144–147
 PMBL, 141–144
 clinical history, 2
 composite lymphomas (*see* Composite lymphomas)
 Cotswold staging classification for, 2, 3
 early-stage, 201–203
 elderly patients, 6, 210, 211
 extranodal involvement, 2
 FL, 140
 germline mutations/polymorphisms, 46
 in immunocompromised patients, 6
 microenvironment (*see* Microenvironment) and NHL, 128
 NLPHL, 140, 141, 212
 patient follow-up and survivorship
 cardiovascular toxicity, 8
 infertility, 8
 secondary malignancies, 7
 patterns of disease progression, 2
 pediatric, 211
 PET-CT, 3
 in pregnancy, 6
 prognostic factors
 clinical factors, 4–5
 PET scan, 5
 pulmonary function test, 4
 risk assessment
 adverse prognostic factors, 197
 chemokines, 199
 EBV, 199
 IPS-3, 198
 IPS-7, 198
 peripheral blood cytokines, 199
 risk factor definitions, 197, 198
 stage IV disease, 198
 SCT, 209
 selected biomarkers, 200
 staging system, 4, 14
 symptoms, 1
 thyroid function testing, 4
 Human leukocyte antigen (HLA), 70, 75
 class I, 165, 177–179
 class II, 179–180
 non-HLA genetic associations, 181–183
 Hypoxic conditions, 42
- I**
 Idelalisib, 226
 Ifosfamide, carboplatin and etoposide (ICE), 206, 223
 Immune escape, 70
- Immunocompromised patients, 6
 Immunoglobulin (Ig) genes, 37, 38
 Immunohistochemistry (IHC), 17, 19, 24, 199
 Immunomodulators, 226
 Immunophenotype, 116, 121
 Incomplete cytokinesis, 39
 Infectious mononucleosis (IM), 91, 94, 163, 164
 Infertility, 8
 Infradiaphragmatic disease, 1
 Interim PET-adapted therapy, 205
 International Prognostic Factors Project on Advanced Hodgkin Disease, 5
 Involved field radiation therapy (IFRT), 201–203, 210, 211
 Involved nodal radiation therapy (INRT), 201, 211
 Ipilimumab, 75, 209
- J**
 JAK/STAT pathway, 45, 68, 118, 143
- K**
 Karyotype, 43
 Kinase insert domain receptor (*KDR*) gene, 176
- L**
 Latent genes, 92, 94–98
 Latent membrane protein-1 (LMP1), 17, 96, 97
 Latent membrane protein-2 (LMP2), 97–98
 Lenalidomide, 226, 227
 LP cells. *See* Lymphocyte-predominant (LP) cells
 Lymphoblastoid cell lines (LCLs), 91, 92
 Lymphocyte-depleted Hodgkin lymphoma (LDHL), 26
 differential diagnosis, 26
 diffuse fibrosis pattern of, 26
 reticular pattern of, 26
 Lymphocyte-predominant (LP) cells, 29, 30, 114, 115, 128
 B cell phenotype, 38
 B-cell antigens, 115
 features of, 36
 GC B cells, 38
 genetic lesions of, 46, 118
 IgV genes, 38
 immunophenotype of, 116
 NF- κ B activity, 46
 PD1-positive T cells, 120
 uninucleated large blasts, 114
 Lymphocyte-rich Hodgkin lymphoma (LRHL), 24

- diagnosis of, 24
- diffuse form of, 23
 - LP-like cells, 23
 - nodular form of, 23
- Lytic genes, 92

- M**
- Macrophages, 61, 62, 66, 69, 72
- Major histocompatibility complex (MHC), 40, 45, 46
- Malaria, 95
- MAP kinase signaling, 48
- Mast cells, 61, 63, 64, 68, 69
- Mechlorethamine, 200
- Mediastinal gray zone lymphoma, 27, 28
- Mediastinal lymphadenopathy, 1
- Melphalan (Mini-BEAM), 205, 207
- Microenvironment
 - CCL5, 64
 - cell types, 61
 - CXCL8, 64
 - host-specific role, 75–76
 - and HRS cells, 79
 - antigen presentation, lack of, 70
 - composition and activity, 63
 - CysLT type 1 receptor, 69
 - cytokines and chemokines, 66–68
 - immune checkpoints, 70–72
 - JAK-STAT signaling, 67, 68
 - receptor tyrosine kinase family members, 69
 - somatic aberrations in, 76–78
 - therapeutic interventions, 73–75
 - tumor necrosis factor receptor superfamily, 68–69
 - miRNAs, 78
 - NLPHL, 119
 - suppressing T-cell responses, 65
 - therapeutic approaches, 65–66
 - therapies targeting cells, 62–63
 - Th1 vs. Th2, 61–62
- Mixed cellularity Hodgkin lymphoma (MCHL), 22
 - age distribution of, 21
 - EBV positive, 22
 - histiocyte-rich variant, 21
 - interstitial fibrosis, 22
- Mocetinostat, 226
- Monomethyl auristatin E, 207
- Mummified cells, 15, 22

- N**
- NanoString technology, 199
- NF- κ B, 44–47, 73, 143
- Nivolumab, 208, 209, 227
- Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), 29–31, 61, 116, 128, 130, 135, 139, 140, 158, 212, 213, 221
 - abundant epithelioid cells, 120
 - B cell phenotype, 38
 - cell line, 117
 - cellular origin, 117
 - and cHL, 46
 - clinical characteristics, 112
 - differential diagnoses, 115–117
 - genetic lesions, 118
 - growth patterns, 112–114
 - heritability of, 176
 - LP cells of, 46
 - microenvironment, 119–121
 - morphologic patterns, 29
 - and PTGC, 28
 - TCRLBCL, 29
 - and THRLBCL, 121
 - tumor cells, 114
- Nodular sclerosis Hodgkin lymphoma (NSHL), 20
 - ALK-negative ALCL, 20
 - ALK-positive ALCL, 20
 - cellular phase of, 19
 - fibrotic bands, 19, 20
 - histopathology of, 19
 - incidence of, 19
 - inflammatory background of, 19
 - lacunar cells, 19
 - lymphocyte-depleted variant of, 19
 - morphologic diagnosis of, 19
- Non-Hodgkin lymphoma (NHL)
 - composite lymphomas
 - cellular origin of, 134–136
 - clonal relationship of, 129
 - definition, 128
 - diagnosis of, 129
 - genetic lesions, 136–140
 - types of, 129
- Novel targeted therapies
 - BV
 - ASCT, bridge to, 223
 - CD30, 222
 - first-in-man phase I trial, 222
 - overall survival (OS) rate, 223
 - PFS, 223
 - relapsed/refractory HL
 - post-ASCT, 222
 - HDACi, 225
 - immunomodulators, 226–227
 - PI3/AKT/mTOR pathway, 226
- Nuclear protein coactivator of histone transcription (NPAT) gene*, 176

P

Panobinostat, 227
 Pathology of Hodgkin lymphoma, 17
 B cell lymphoma, unclassifiable, 27
 CHL (*see* Classical Hodgkin lymphoma (CHL))
 NLPHL, 28–29
 Pembrolizumab, 208, 209, 227
 Peripheral blood cytokines, 199
 PET-CT. *See* Positron emission tomography–computed tomography (PET-CT)
 Plasma cells, 37, 64, 92, 93, 98, 99
 Polymorphisms, 46
 Positron emission tomography (PET), 1, 3, 5, 7, 197, 200, 203, 205, 206, 208, 223
 Positron emission tomography–computed tomography (PET-CT), 3, 4
 Prednisone, 197, 200, 211
 Pregnancy, Hodgkin lymphoma in, 6
 Pretransplant salvage therapy, 207
 Primary mediastinal B-cell lymphoma (PMBL), 27, 130, 133, 140–144
 Procarbazine, 197
 Programmed cell death ligand-1 (PD-L1), 101, 143
 Progressive multifocal leukoencephalopathy (PML), 225
 Progressive transformation of germinal centers (PTGC), 28, 31, 116, 121
 Protein arginine methyltransferases, 97
 Proton therapy, 211
 Pulmonary toxicity, 208
 Pyrothorax-associated lymphoma (PAL), 95

R

Receptor tyrosine kinases (RTK), 47, 48, 69, 97
 Reduced intensity conditioning (RIC) regimens, 209
 Response-adapted therapy, 200–203, 211
 Response-Adapted Therapy in Advanced Hodgkin Lymphoma (RATHL), 205
 Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, 213

S

Secondary malignancies, 7–8
 Second-line salvage therapies, 210
 Shelter in proteins, 97
 Socioeconomic status (SES), 158, 165, 166, 168
 Somatic hypermutation, 93, 96, 135
 Somatic mutations, 37, 47, 135
 Splenomegaly, 1
 Staging system, 2, 4
 Subtotal nodal irradiation (STNI), 202

T

T cell/histiocyte rich large B-cell lymphoma (THRLBCL), 29, 114, 117, 118, 121
 T cell receptor (TCR) gene, 37
 T cells, 37, 40
 double negative, 95
 EBV-specific cytotoxic, 45
 GATA3, 46
 immunophenotype, 116
 and NK cells, 45
 PD1 receptor, 45
 Temsirolimus, 227
 T helper (Th) cells, 61
 Thrombocytopenia, 226
 Thymus and activation-related chemokine (TARC), 199
 Tonsillectomy, 168
 T regulatory (Treg) cells, 61, 62, 64, 65, 70, 74
 Tumor-associated macrophages (TAMs), 100, 199, 200
 Tumor necrosis factor (TNF) family, 17, 222

U

Upfront risk stratification tools, 197

V

Vascular endothelial growth factor (VEGF), 176
 Vinblastine, 200
 Vincristine, 197, 200, 211
 Viral capsid antigen (VCA), 163–165